Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Orexigen’s Contrave May Win In The End

Executive Summary

The biotech finally gleaned an FDA approval for its obesity pill Contrave and now faces the hurdle of commercialization, but plans to profit by the lessons from its competitors’ missteps.

You may also be interested in...

Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management

Advisory committee members are generally comfortable with use of the GLP-1 receptor agonist in the first-line setting, suggesting that a second-line treatment restriction in diabetes could be lifted.

Orexigen Thinks Contrave On The Verge Of Approval, Again

The biotech once again faces an FDA approval decision for its bupropion/naltrexone obesity combo, after a long and costly cardiovascular outcomes trial has kept the drug off the market.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts